YAZ
LOE ApproachingNDAORALTABLET
Approved
Jan 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
5/8 — Partial
YAZ by Bayer is ovulation. Approved for symptoms of premenstrual dysphoric disorder (pmdd) in females of reproductive potential, moderate acne vulgaris in women at least 14 years of age. First approved in 2007.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YAZ is an oral contraceptive tablet approved by the FDA in January 2007 as a small-molecule NDA. The drug's specific mechanism of action and clinical indications are not fully characterized in the available data, but it is marketed by Bayer as an oral contraceptive product. It represents a mature, established product in the women's health category.
$0.114BPart D
LOE ApproachingProduct approaching loss of exclusivity with moderate Part D claims; commercial team likely consolidating around retention strategies rather than growth initiatives.
Mechanism of Action
ovulation.
Worked on YAZ at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.